Synthesis and antidepressant activities of aryl alkanol piperidine derivatives

Yaoxue Xuebao

Volumn 45, Issue 3, 2010, Pages 324-329

  Zheng, Yong Yong ^a   Gao, Kai ^b   Weng, Zhi Jie ^a   Li, Jian Qi ^a  

^a SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY   (China)

^b Jiangsu Huizhong Pharmatech Co Ltd   (China)

Author keywords

Antidepressant activity; Aryl alkanol piperidine derivative; Monoamine reuptake inhibitor; Synthesis

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; 1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANAMINE; ANTIDEPRESSANT AGENT; PAROXETINE; PIPERIDINE DERIVATIVE; SIPI 5286; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; DRUG DESIGN; DRUG SYNTHESIS; FORCED SWIMMING TEST; HUMAN; MASS SPECTROMETRY; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; ANTIDEPRESSIVE AGENTS; DOPAMINE; MALE; MICE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; PIPERIDINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP; SWIMMING; SYNAPTOSOMES;

EID: 77952217352     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. WHO the world health report 2001, mental health: new understanding, new hope [EB/OL]. http://www.who.int/whr/2001/en/.
2. World pharma sales 2001: US still driving growth [EB/OL]. http://wwwl.imshealth.com/web/content/0,3148,64576068-63872702-70260998- 70328515.00.html.
3. Skolnick P, Popik P, Janowsky A, et al. "Broad spectrum" antidepressants: is more better for the treatment of depression? [J]. Life Sci, 2003, 73: 3175-3179.
4. Skolnick P, Popik P, Janowsky A, et al. Antidepressant-like actions of DOV 21947: a "triple" reuptake inhibitor [J]. Eur J Pharmacol, 2003, 461: 99-104.
5. Barberich TJ. Sepracor Presents at 22nd Annual JPMorgan Healthcare Conference and Highlights New Clinical Programs [C]. San Francisco: J.P. Morgan 22nd Ann Healthcare Conference, 2004.
6. Li JQ, Huang LY, Dong WX, et al. Aryl alkanol piperazine derivatives and their uses as antidepressants: US, 2005267121A1 [P]. 2005-12-101
7. Petukhov PA, Zhang J, Kozikowski AP, et al. SAR studies of piperidine-based analogues of Cocaine. 4. Effect of N-modification and ester replacement [J]. J Med Chem, 2002, 45: 3161-3170.
8. Webb MB, Stack GP, Asselin M, et al. Antidepressant piperidine derivatives of heterocycle-fused benzodioxans: US, 6939877 [P]. 2003-09-10.
9. El Ahmad Y, Fiez-Vandal PY, Laurent E, et al. N-(benzhydryloxyalkyl)-4- (carboxy/carbamoyl methyl)-piperidine derivatives as antidepressants: US, 5846980 [P]. 1998-12-108
10. van Niel MB, Collins I, Beer MS, et al. Fluorination of 3-(3-(piperidin-1-yl) propyl)indoles and 3-(3-(piperazin-1-yl) propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles [J]. J Med Chem, 1999, 42: 2087-2104. (Pubitemid 29284229)
11. Gray AP, Bedford V, Heitmeier DE, et al. Treatment of depression with 4-substituted piperidines: US, 3632767 [P]. 1968-02-12.
12. Borza I, Horváth C, Farkas S, et al. New 4-benzylidene-piperidin derivatives: WO, 2006010964 [P]. 2006-02-02
13. 1-42 aggregation for Alzheimer's disease therapeutics [J]. Bioorg Med Chem, 2007, 15: 6596-6607.